Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 5 de 5
Filtrer
Plus de filtres











Gamme d'année
1.
Schizophr Res ; 268: 252-260, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38151432

RÉSUMÉ

There is no established treatment for patients with clozapine-resistant schizophrenia (CRS). Clozapine augmentation strategies with antipsychotics or others substances are effective in comparison with placebo while and Electroconvulsive therapy (ECT) showed to be effective in comparison with treatment as usual (TAU) but not with placebo (sham-ECT). In the present double- blind randomized controlled trial, we compared 40 outpatients who received 20 sessions of ECT (n = 21) or sham-ECT (n = 19) (age = 37.40 ± 9.62, males = 77.5 %, illness duration = 14.95 ± 8.32 years, mean total Positive and Negative Syndrome Scale (PANSS) = 101.10 ± 24.91) who fulfilled well-defined CRS criteria including baseline clozapine plasma levels ≥350 ng/mL. The primary outcome was the ≥50 % PANSS Total Score reduction; secondary outcomes were the scores of the PANSS subscales, PANSS five-factor dimensions, PANSS-6 and the Calgary Depression Rating Scale (CDRS). Treatment response was analyzed by percentage reduction, Linear Mixed Models and effect sizes. At baseline both groups showed no differences except for years of school education (included as a covariate). At endpoint, only 1/19 of the completers (5.26 %) in the ECT group and 0/17 in the sham-ECT group showed a ≥50 % total PANSS score reduction. Both groups showed no significant differences of the total PANSS score (F = 0.12; p = 0.73), Positive (F = 0.27, p = 0.61), Negative (F = 0.25, p = 0.62), and General Psychopathology scores (F = 0.01, p = 0.94) as well for all PANSS five factors, the PANSS-6 and CDRS. Thus, the present study found no evidence that ECT is better than Sham-ECT in patients with CRS. Future sham-ECT controlled studies with larger sample sizes are warranted to test the efficacy of ECT for patients with CRS.


Sujet(s)
Neuroleptiques , Clozapine , Électroconvulsivothérapie , Schizophrénie résistante au traitement , Humains , Mâle , Femelle , Électroconvulsivothérapie/effets indésirables , Adulte , Clozapine/usage thérapeutique , Clozapine/effets indésirables , Méthode en double aveugle , Neuroleptiques/usage thérapeutique , Adulte d'âge moyen , Schizophrénie résistante au traitement/thérapie , Schizophrénie résistante au traitement/traitement médicamenteux , Échelles d'évaluation en psychiatrie , Résultat thérapeutique , Schizophrénie/thérapie , Schizophrénie/traitement médicamenteux , 29918
2.
Bull Entomol Res ; 111(5): 568-578, 2021 Oct.
Article de Anglais | MEDLINE | ID: mdl-33858528

RÉSUMÉ

The Mediterranean fruit fly, Ceratitis capitata (Wiedemann), is one of the main pests of fruit, worldwide, and the use of population suppression method with low environmental impact is an increasingly strong requirement of the consumer market. The aim of this study was to evaluate the effect of mineral and natural films on the physical-chemical properties of grapes (Vitis vinifera L.), cultivar Itália, and oviposition behaviour of C. capitata. Fruits were immersed in suspensions (100 and 200 g L-1) of mineral (kaolin Surround®WP, kaolin 607, kaolin 608, kaolin 611 and talc) and natural films (chitosan, cassava starch, potato starch and guar gum 5.0 g L-1) and distilled water (control). After drying, fruits were exposed to C. capitata pairs of males and females for 24 h in choice and non-choice tests; the number of punctures with and without eggs, eggs per fruit and behavioural response of fly to treated and untreated fruits were recorded. Results obtained in this study are promising, given the scientific evidence that films of mineral particles such as kaolin (Surround®, 607, 608 and 611) changed the firmness, luminosity, chroma and hue angle of grapes and reduced the oviposition of C. capitata. In addition, our results also showed that natural polymers do not deter C. capitata females, but rather seem to stimulate oviposition.


Sujet(s)
Ceratitis capitata/physiologie , Films , Oviposition , Vitis , Animaux , Femelle , Fruit , Kaolin , Mâle , Polymères , Talc
4.
Rev. ciênc. farm ; 25(1): 59-64, 2004. graf
Article de Portugais | LILACS | ID: lil-418915

RÉSUMÉ

Foi realizada uma pesquisa junto aos profissionais farmacêuticos no município de Curitiba, no estado do Paraná, Brasil, com o objetivo de buscar informações necessárias à dispensão de medicamentos específicos ao portador de diabetes mellitus. Observou-se a falta de conhecimento no que se refere à temática abordada, incluindo procedimentos e produtos. Na discussão apresentou-se uma análise crítica dos resultados e inseriu-se os aspectos cognitivos necessários à elucidação de inúmeras dúvidas encontradas junto aos profissionais. Para tanto, propõe-se medidas de atualização sobre o diabetes mellitus pelo profissional farmacêutico, demonstrando-se as vantagens em promover o esclarecimento das dúvidas dos pacientes no momento da dispensação e, propõe-se a incorporação, no cotidiano do profissional, da atenção farmacêutica nos cuidados primários à saúde do portador do diabetes


Sujet(s)
Humains , Diabète , Services pharmaceutiques , Pharmaciens , Soins de santé primaires
5.
Arq Neuropsiquiatr ; 52(2): 210-5, 1994 Jun.
Article de Anglais | MEDLINE | ID: mdl-7826249

RÉSUMÉ

Carbamazepine and amiodarone may often be used together, especially in countries where cardiomyopathies are common. In this study single doses of carbamazepine (400 mg) were given to patients with cardiac disease before and after one month of therapy with amiodarone, 400 mg daily. The kinetic profile of carbamazepine, its free fraction, and serum amiodarone, were measured at the two occasions. There was no statistically significant change in carbamazepine kinetics or free fraction, before and after the introduction of amiodarone. The concentrations of amiodarone after one month of therapy were low. It is suggested that the possible interaction in the hepatic metabolism was not demonstrated because amiodarone concentrations were not enough to inhibit carbamazepine metabolism.


Sujet(s)
Amiodarone/administration et posologie , Carbamazépine/pharmacocinétique , Maladie de Chagas/métabolisme , Ischémie myocardique/métabolisme , Adulte , Sujet âgé , Amiodarone/pharmacocinétique , Carbamazépine/administration et posologie , Interactions médicamenteuses , Association de médicaments , Femelle , Humains , Mâle , Adulte d'âge moyen , Études prospectives
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE